Research site
Silver Spring, Maryland 20910
5 studies enrolling now · 27 studies all time
What they study most
Advanced Breast Cancer, Asthma, Breast Cancer, Early Breast Cancer, Breast Cancer; HER2-positive; Metastatic, COVID-19, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Chronic Kidney Disease With High Proteinuria, Chronic Kidney Diseases, ER-Positive HER2-Negative Breast Cancer, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma
Studies at this site
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer — Recruiting now
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer — Recruiting now
- Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) — Recruiting now
- Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen — Recruiting now
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — Recruiting now
- Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma — Recruiting now
- A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer — Recruiting now
- A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC — Recruiting now
- Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) — Running, not enrolling
- A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. — Running, not enrolling
- Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation — Running, not enrolling
- A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations — Running, not enrolling
- A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) — Running, not enrolling
- Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) — Running, not enrolling
- ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) — Running, not enrolling
- Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC — Running, not enrolling
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease — Running, not enrolling
- Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE) — Completed
- A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer — Running, not enrolling
- A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease — Completed
- Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) — Completed
- Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status — Completed
- Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. — Completed
- P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis — Stopped early
- Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer — Completed
- Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis — Completed
- A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults — Completed